The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VIVS | -70.57% | -98.57% | -57.21% | -100% |
| S&P | +17.45% | +75.43% | +11.88% | +399% |
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $26.00K | 8.3% |
| Gross Profit | -$26.00K | 42.2% |
| Gross Margin | -100.00% | 87.5% |
| Market Cap | $4.72M | -40.1% |
| Market Cap / Employee | $363.11K | 0.0% |
| Employees | 13 | -35.0% |
| Net Income | -$2,691.00K | 21.9% |
| EBITDA | -$2,698.00K | 20.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.29M | 269.3% |
| Accounts Receivable | $33.00K | 26.9% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.00K | -91.9% |
| Short Term Debt | $768.00K | -0.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -22.71% | 171.9% |
| Return On Invested Capital | -106.43% | 9.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,271.00K | -26.1% |
| Operating Free Cash Flow | -$2,271.00K | -26.1% |
| Metric | Q4 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 3.89 | - | |||
| Price to Book | 8.79 | 0.27 | 0.80 | 0.67 | -96.91% |
| Price to Sales | 29.53 | 25.92 | 54.33 | 33.24 | -51.16% |
| Price to Tangible Book Value | 8.79 | 0.27 | 0.80 | 0.67 | -97.10% |
| Enterprise Value to EBITDA | 1.94 | 1.60 | -0.77 | -0.46 | -81.46% |
| Return on Equity | -35.3% | -24.5% | -36.9% | -51.1% | -86.50% |
| Total Debt | $1.07M | $822.00K | $1.05M | $812.00K | -38.34% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
